Results 91 to 100 of about 78,382 (206)
BRAF-Inhibitor auch langfristig effektiv [PDF]
Im Focus Onkologie, 2012 Etwa 50 % der malignen Melanome weisen aktivierende Mutationen (V600-Mutationen) in der Serin-Threonin-Proteinkinase BRAF auf. Was kann der orale BRAF-Inhibitor Vemurafenib bei diesen Patienten leisten?
openaire +1 more source
Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
EMBO Molecular Medicine, 2017 Approaches to prolong responses to BRAF targeting drugs in melanoma patients are challenged by phenotype heterogeneity. Melanomas of a “MITF‐high” phenotype usually respond well to BRAF inhibitor therapy, but these melanomas also contain subpopulations ...
Michael P Smith +20 more
doaj +1 more source
Therapeutic Potential of Black Pepper Compound for BRaf Resistant Melanoma
Proceedings, 2017 Malignant melanoma is significant problem for Caucasian population in the western countries. Mutations in BRAF gene in 60% of patients is responsible for developing resistance to BRAF inhibitors.
Neel M. Fofaria +2 more
doaj +1 more source
Frontiers in OncologyBackgroundThe Food and Drug Administration has approved the Serine/threonine-protein kinase B-raf (BRAF) inhibitor and Mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor combo as the first-line treatment for individuals with ...
Xing Luo +8 more
doaj +1 more source
Patient-derived iPSCs show premature neural differentiation and neuron type-specific phenotypes relevant to neurodevelopment. [PDF]
, 2018 Ras/MAPK pathway signaling is a major participant in neurodevelopment, and evidence suggests that BRAF, a key Ras signal mediator, influences human behavior.
Camacho, FM +10 more
core
Frontiers in PharmacologyAimCutaneous adverse events (CAEs) after treatment with BRAF and MEK inhibitors in patients with melanoma remain incompletely characterized. To determine the association of BRAF and MEK inhibitor treatment with CAEs in patients with melanoma compared ...
Junhui Qian +6 more
doaj +1 more source
LNK suppresses interferon signaling in melanoma. [PDF]
, 2019 LNK (SH2B3) is a key negative regulator of JAK-STAT signaling which has been extensively studied in malignant hematopoietic diseases. We found that LNK is significantly elevated in cutaneous melanoma; this elevation is correlated with hyperactive ...
Ding, Ling-Wen +19 more
core
Next-generation sequencing of prostate cancer: genomic and pathway alterations, potential actionability patterns, and relative rate of use of clinical-grade testing. [PDF]
, 2019 Despite being one of the most common cancers, treatment options for prostate cancer are limited. Novel approaches for advanced disease are needed. We evaluated the relative rate of use of clinical-grade next generation sequencing (NGS) in prostate cancer,
Carter, Jennifer L +4 more
core
MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). [PDF]
, 2017 A pancreatic ductal adenocarcinoma (PDAC), obtained from a patient, was grown orthotopically in the pancreatic tail of nude mice to establish a patient-derived orthotopic (PDOX) model.
Bouvet, Michael +10 more
core